Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

Running, not enrolling · Phase 2

Conditions studied: HIV-1 Infection

In brief

The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologically suppressed people with HIV (PWH) at Week 24.

Key facts

Study ID
NCT05052996
Run by
Gilead Sciences
People needed
142
Starts
2021-10-05
Expected to finish
2028-03-01
Last updated by the study team
2026-02-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.